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Background: Elevated biomarkers of systemic inflammation have been reported in
individuals with cognitive decline, however, most of the literature concerns cross-
sectional analyses that have produced mixed results. This study investigates the etiology
of this association by performing meta-analyses on prospective studies investigating the
relationship between baseline interleukin-6 (IL-6), an established marker of peripheral
inflammation, with cognitive decline risk in non-demented adults at follow-up.
Methods: We reviewed studies reporting peripheral IL-6 with future cognitive decline, up
to February 2017 by searching the PubMed, Science Direct, Scopus and Google Scholar
databases. Studies which contained odds ratios (ORs) for the association between
circulating baseline IL-6 and longitudinal cognitive performance in non-demented
community dwelling older adults were pooled in random-effects models.
Results: The literature search retrieved 5,642 potential articles, of which 7 articles
containing 8 independent aging cohorts were eligible for review. Collectively, these
studies included 15,828 participants at baseline. Those with high circulating IL-6 were
1.42 times more likely to experience global cognitive decline at follow-up, over a 2–7-
year period, compared to those with low IL-6 (OR 1.42, 95% CI 1.18–1.70; p < 0.001).
Subgroup and sensitivity analyses suggests that this association is independent of the
study sample size, duration of follow-up and cognitive assessments used.
Conclusions: These results add further evidence for the association between high
peripheral inflammation, as measured by blood IL-6, and global cognitive decline.
Measuring circulating IL-6 may be a useful indication for future cognitive health.
Keywords: inflammation, cognitive aging, inflammaging, interleukin-6, meta-analysis, cognitive decline,
longitudinal studies, prospective studies
INTRODUCTION
Globally, the number of older adults (≥60 years old) is projected to increase by 56%, from 901
million to 1.4 billion, over the next 14 years and surpass 2 billion by the year 2050 (United Nations,
2015). Analysis involving European studies of aging suggest that the prevalence of cognitive decline
in older adults is as high as 28% (Scafato et al., 2010). Some, but not all, of those who experience
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cognitive decline may go on to develop mild cognitive
impairment (MCI). Those with MCI are then at an increased risk
of developing dementia (Korolev et al., 2016). The underlying
pathogenesis behind this heterogenous transition from cognitive
aging to dementia is still under debate but, evidence suggests
that systemic inflammation may be a contributing factor
(Cunningham and Hennessy, 2015).
Systemic inflammation gradually increases with age,
commonly referred to as inflamm-aging. Of the cytokines
implemented in the inflamm-aging process, interleukin-6 (IL-6)
is regarded as one of the main inflammatory components
resulting in the age-associated pathologies (Franceschi and
Campisi, 2014). Physiologically, IL-6 is a hormone-like cytokine
with pleiotropic capabilities including roles in immunological
homeostasis (Hunter and Jones, 2015), such as upregulating
acute phase response proteins (e.g., C-reactive protein), and
signaling within the central nervous system (CNS) (Spooren
et al., 2011; Erta et al., 2012).
Dysregulation of IL-6 has been implicated in the modulation
of various cognitive functions (Donzis and Tronson, 2014)
and previous meta-analyses have reported associations between
upregulated peripheral IL-6 with Alzheimer’s disease (AD)
(Swardfager et al., 2010; Lai et al., 2017) and postoperative
cognitive dysfunction (Peng et al., 2013). These studies report
associations between peripheral inflammation during and after
the onset of neuropathologies. Exploring these associations
longitudinally in the non-demented, however, may provide a
better insight into the pathological roles peripheral inflammation
plays in the CNS.
The current state of the literature concerning IL-6 and
cognitive decline in prospective cohorts of old adults has so far
produced mixed findings (Weaver et al., 2002; Yaffe et al., 2003;
Dik et al., 2005; Jordanova et al., 2007; Rafnsson et al., 2007;
Schram et al., 2007; Singh-Manoux et al., 2014), with some stating
a significant association between baseline IL-6 with cognitive
decline while others failed to replicate such results. Further,
systematic analyses remain inconclusive (Li and Yu, 2017).
The aim of this study was to collate the current data from
the literature and perform a meta-analysis for longitudinal
studies reporting the association between baseline peripheral IL-
6 and future cognitive decline in adults without dementia. This
approach is warranted in order to increase the statistical power
and thus provide clarity to such an association.
METHODS
Search Strategy
All analyses were performed according to the PRISMA guidelines
(Liberati et al., 2009). We searched the published literature in the
Scopus, PubMed, Science Direct and Google Scholar databases
up to February 2017.
Search terms were as follows: (“Interleukin-6” OR “IL-
6”) AND (cognition OR “cognitive decline” OR “cognitive
function” OR “cognitive impairment” OR “cognitive loss” OR
memory) AND (aging OR aging) AND (health OR healthy) AND
(longitudinal OR prospective). We also manually searched any
relevant references cited within retrieved articles. A standardized
review protocol has not been published.
Eligibility Criteria
Studies were included if they met the following criteria: (i) a
prospective cohort design; (ii) cognition performance was used
at baseline and at follow-up; (iii) non-demented older subjects
at baseline; (iv) IL-6 measured in unstimulated blood (e.g.,
ex vivo blood was not stimulated by lipopolysaccharide); (v)
reported odds ratios (ORs) for the association of baseline IL-
6 and future global cognitive decline; (vi) the study population
consisted of community-dwelling adults; (vii) the article was
available in English. Exclusion criteria included: (i) participants
with dementia or cognitive impairment were included at baseline;
(ii) the association between baseline IL-6 and cognitive decline
was not reported; (iii) the study design was cross-sectional or
interventional.
Where multiple publications utilized the same cohort source,
the study containing the majority of required data was preferred.
Where studies reported alternative statistics, as opposed to ORs,
authors were contacted via e-mail and the desired logistical
analysis was requested. Two authors agreed to this approach
(Rafnsson et al., 2007; Schram et al., 2007) and provided ORs.
Unsuccessful requests were otherwise discarded from the review.
Data Extraction
All data were reviewed and extracted by two independent
investigators (SB and CM). Results were compared and
disagreements were settled through discussion.
The following characteristics and data were extracted from
each paper: number of subjects at baseline, proportion of females
at baseline, age at baseline, length of study follow-up, assessment
of global cognition, OR and 95% confidence intervals (CIs) for
adjusted model, and confounders adjusted for in the regression
analysis. Where studies stratified subjects into more than two
groups (e.g., tertiles, quartiles), high and low IL-6 are defined
as those in the highest and lowest grouping, respectively. For
studies categorizing IL-6 into two groups, via a median split,
high and low IL-6 subjects are defined as those above and below
the median. For those reporting tertile groupings, those in the
second tertile were classed as intermediate IL-6. Where multiple
cognitive assessments were used to assess different cognitive
domains, we chose the assessment and outcome reflecting global
cognitive decline. Where multiple model testing was applied,
we extracted the model with the most adjustments for potential
confounders.
Quality Assessment
Each paper included within the meta-analyses was subject to
quality assessment by two authors via the Newcastle-Ottawa
Quality Assessment Scale for cohort studies (Wells et al., 2000).
This scale is based on three categories (population selection,
comparability and outcome) with a combined maximum score
of 9 points. Ratings were compared between authors and
disagreements were settled through discussion.
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Statistical Analysis
The Review Manager (RevMan; version 5.3.5; Copenhagen,
Denmark) software was used to pool the individual studies of
interest. Results were deemed statistically significant when p <
0.05. Analysis is presented as ORs based on the likelihood of
cognitive decline in the highest baseline IL-6 group compared to
the lowest group using a random-effects method.
To investigate heterogeneity between studies, we used the
I2 index which describes the percentage of variation across the
studies in the pooled analysis that is due to inconsistency rather
than by chance.
Post-hoc sensitivity analyses were carried out to investigate the
impact of between study methodological difference on the meta-
analyses including, follow up time, cohort size, Newcastle-Ottawa
Quality Assessment Scale score and IL-6 measurement method
and grouping, as appropriate.
Publication bias was assessed through visual inspection of
each Begg’s funnel plot and the Egger’s test. Analysis was
performed using the Stata (StataCorp LP; version 14.2; College
Station, TX, USA) software.
RESULTS
Study Selection
Our search strategy returned 5,642 potential articles for inclusion
on baseline IL-6 and prospective cognitive functioning, of which
70 were deemed relevant through title and abstract screening
(Figure 1). After the removal of duplicate findings, 34 articles
remained for full-text analysis. Of these, 27 articles were excluded
as they did not meet our inclusion criteria, leaving 7 articles
eligible for review. Schram et al. (2007) reported two independent
cohorts (Rotterdam and Leiden 85-plus), therefore these were
treated as separate studies. Thus, in total 8 studies were included
in the review and the study characteristics are described in
Table 1. Quality assessment determined that all studies had a high
quality score (range: 7–9) (Table 2) with an agreement rate of
86% between author ratings.
Study Characteristics
In total the studies contained 15,828 participants at baseline.
Three studies (Yaffe et al., 2003; Rafnsson et al., 2007; Singh-
Manoux et al., 2014) reported proportions of global cognitive
decline upon follow-up (8,700 at baseline; 792 declined at follow-
up; 9%). All the studies contained a mix of male and female
participants. Follow-up periods ranged from 2 to 7 years.
Two studies measured IL-6 from the serum (Dik et al., 2005;
Singh-Manoux et al., 2014) and six, including both independent
cohorts presented in the Schram et al. study, measured IL-6
from plasma (Weaver et al., 2002; Yaffe et al., 2003; Jordanova
et al., 2007; Rafnsson et al., 2007; Schram et al., 2007). All the
studies quantified IL-6 from the blood by using an enzyme-linked
immunosorbent assay (ELISA) technique.
Assessments of global cognitive functioning consisted of
either the Mini-Mental State Examination (MMSE), Modified
MMSE (3MS) or a battery of assessments (Table 3). Further, the
definition of global cognitive decline differed between studies,
however, three of the studies which used the MMSE as the
assessment (Schram et al., 2007; Singh-Manoux et al., 2014) had
identical definitions (Table 3). All studies included adjustments
for age, gender and education at a minimum in their models
(Table 3).
Association between High Baseline IL-6
and Global Cognitive Decline:
Meta-Analysis
Those with high baseline IL-6 were 1.42 times more likely to
encounter global cognitive decline at follow-up, compared to
those with low IL-6 (OR 1.42, 95% CI 1.18–1.70, p < 0.001;
FIGURE 1 | Flowchart summarizing the literature search for the meta-analysis.
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TABLE 1 | Study characteristics included in the meta-analysis.
Paper Cohort (location) Subjects at
baseline (n)
Female (%) Mean age at baseline
(years)
Mean follow
up (years)
Dik et al., 2005 Longitudinal Aging Study Amsterdam
(The Netherlands)
1,284 51 75.4 ± 6.6 3
Jordanova et al., 2007 N/A (Britain) 290 57 65.5 ± 5.5 3
Rafnsson et al., 2007 Edinburgh Artery Study (Britain) 452 50 73.1 ± 5.0 4
(Schram et al., 2007) (Leiden 85-Plus
cohort)
Leiden 85-Plus cohort (The
Netherlands)
491 65 85 3.4
(Schram et al., 2007) (Rotterdam cohort) Rotterdam cohort (The Netherlands) 3,874 58 72.1 ± 6.9 4.6
Singh-Manoux et al., 2014 The Whitehall II Study (Britain) 5,217 28 55.7 ± 6.0 5
Weaver et al., 2002 The MacArthur Study of Successful
Aging (America)
1,189 55 74.3 ± 2.7 7
Yaffe et al., 2003 The Health ABC Study (America) 3,031 52 73.6 ± 2.9 2
Figure 2A). No study heterogeneity was evident (I2 = 14%,
p= 0.32; Figure 2A).
Association between High Baseline IL-6
and Global Cognitive Decline: Subgroup
Analysis
Subgroup analysis determined the association was independent
of the sample size used (<1,000/≥1,000 participants at baseline),
duration of follow-up (<4/≥4 years) and the method used to
assess global cognitive performance (MMSE/others) (Table 4).
The association, however, was no longer evident when including
only studies of lower quality (<8 points). The significance
remained after removing studies which categorized IL-6 as
above/below median (Weaver et al., 2002; Dik et al., 2005), as
opposed to upper and lower grouping (OR 1.41, 95% CI 1.16–
1.71; p< 0.001; 6 studies) and those which used serum tomeasure
IL-6 (Dik et al., 2005; Singh-Manoux et al., 2014) opposed to
plasma (OR 1.39, 95% CI 1.14–1.69; p= 0.001; 6 studies).
Association between High Baseline IL-6
and Global Cognitive Decline: Risk of Bias
Analysis
No publication bias was evident based on visual inspection
of Begg’s funnel plot (Figure 3A) or through an Egger’s test
(p= 0.379).
Association between Intermediate
Baseline IL-6 and Global Cognitive Decline:
Meta-Analysis
Five of the aforementioned studies (Weaver et al., 2002; Rafnsson
et al., 2007; Schram et al., 2007; Singh-Manoux et al., 2014) also
provided data for the association of cognitive decline in those
with intermediate (second tertile group) baseline concentrations
of IL-6. There was no significant association between those
with intermediate baseline IL-6 and the likelihood of cognitive
decline at follow-up, compared to those with low IL-6 (OR 1.13,
95% CI 0.90–1.42; p = 0.28; Figure 2B). No significant study
heterogeneity (I2 = 0%, pP= 0.59; Figure 2B) was evident.
TABLE 2 | Quality assessment of the included studies via the Newcastle-Ottawa
Quality Assessment Scale.
Study Selectiona Comparabilityb Outcomec Total
Weaver et al., 2002 **** ** ** 8
Yaffe et al., 2003 **** ** *** 9
Dik et al., 2005 *** ** ** 7
Jordanova et al., 2007 ** ** *** 7
Rafnsson et al., 2007 *** ** *** 8
(Schram et al., 2007)
(Rotterdam cohort)
**** ** ** 8
(Schram et al., 2007)
(Leiden 85-plus cohort)
*** ** *** 8
Singh-Manoux et al., 2014 ** ** *** 7
Scores per section are presented as asterisks. * = one point. Only those answers with an
asterisk are given a score. aSelection; (1) Representativeness of the exposed cohort
(high/intermediate IL-6 group): (a) Truly representative of the average community-
dwelling older adults*. (b) Somewhat representative of the average community-dwelling
older adults*. (c) Selected group of users e.g., nurses, volunteers. (d) No description of the
derivation of the cohort. (2) Selection of the non-exposed cohort (low IL-6 group):
(a) Drawn from the same community as the exposed cohort*. (b) Drawn from a different
source. (c) No description of the derivation of the non-exposed cohort. (3)Ascertainment
of IL-6 category: (a) Quantified from blood (unstimulated) using an appropriate technique
(e.g., ELISA)*. (b) No description. (4) Demonstration that dementia was not present
at start of study: (a) Yes – assessed via interview or using an established cognitive test*.
(b) No - presumed. bComparability; (1) Comparability of cohorts on the basis of the
design or analysis: a) Study controls for age AND gender in analysis*. (b) Study controls
for education level or prior cognitive ability in analysis*. cOutcome; (1) Assessment of
outcome: (a) Cognitive test (e.g., MMSE) which was the same as baseline*. (b) Self
report. (d) No description. (2) Was follow-up long enough for outcomes to occur:
(a) Yes (average ≥ 2 years)*. (b) No (average < 2 years). (3) Adequacy of follow up of
cohorts: a) Complete follow up - all subjects accounted for*. (b) Subjects lost to follow up
unlikely to introduce bias - small number lost (≤ 25%), or description provided of those lost
suggesting no different from those followed*. (c) Follow up rate ≤50% and no description
of those lost. (d) No statement.
Association between Intermediate
Baseline IL-6 and Global Cognitive Decline:
Risk of Bias Analysis
No publication bias was observed when visually inspecting the
Begg’s funnel plot (Figure 3B) and through an Egger’s test
(p= 0.216).
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TABLE 3 | Summary of global cognitive assessments and definitions used in each study included in the meta-analysis.
Paper Cognitive test Global cognitive decline
definition
IL-6 categories (pg/mL) Blood specimen Model adjustments
Dik et al., 2005 MMSE Change based on cognitive
test and regression to the
mean.
Low: <5.0
High: 5.0–58.3
Serum Age, gender, education.
Jordanova et al., 2007 Battery Factor analysis based on
cognitive score change.
Low: ≤3.1
High: >3.1
Plasma Age, gender, education, stroke,
hypertension, diabetes, smoking,
alcohol status, BMI, NSAID use,
disability.
Rafnsson et al., 2007 Battery ≥ 1 standard deviations
from a general cognitive
factor value.
Low: 0.55–1.66
Intermediate: 1.67–3.00
High: 3.01–100
Plasma Age, gender, depressed mood,
peak prior cognitive ability,
lifetime smoking, alcohol intake,
presence of major cardiovascular
diseases, presence of diabetes
mellitus.
(Schram et al., 2007)
(Leiden 85-Plus cohort)
MMSE ≥3 points in MMSE scores. Low: 0–4
Intermediate: 5–25
High: 26–75,001
Plasma Age, gender, education.
(Schram et al., 2007)
(Rotterdam cohort)
MMSE ≥3 points in MMSE scores. Low: 0.53–1.82
Intermediate: 1.82–3.09
High: 3.10–80
Plasma Age, gender, education.
Singh-Manoux et al.,
2014
MMSE ≥3 points in MMSE scores. Low: <1.18
Intermediate: 1.18–1.74
High: ≥1.75
Serum Age, gender, ethnicity, education,
smoking, obesity, Framingham
cardiovascular disease risk
score, coronary heart disease,
stroke, cancer, diabetes
antidepressant use.
Weaver et al., 2002 Battery ≥7 points in cognitive score. Low: <2.13
Intermediate: 2.13–3.8
High: ≥3.8
Plasma Age, race, gender, yearly
income, education level, alcohol
intake, activity level, BMI,
self-reported history of cancer or
diabetes, HBA1c levels, baseline
cognitive scores.
Yaffe et al., 2003 3MS >5 points in 3MS scores, or
if taking cholesterase
inhibitor, or hospitalized for
dementia.
Low: 0.2–1.4
High: 2.4–16.0
Plasma Age, education, race, gender,
smoking, alcohol use, BMI,
self-reported health,
co-morbidities, baseline 3MS,
use of NSAID.
DISCUSSION
Individually, many studies included within these analyses did not
report significant findings. However, from a collective analysis
containing 15,828 older adults who were community-dwelling at
baseline, those with high baseline IL-6 were 1.42 timesmore likely
to develop global cognitive decline during a follow-up period of
2–7 years, compared to those with low IL-6.
This is the first meta-analysis to investigate baseline IL-
6 and longitudinal global cognitive decline in non-demented
adults. Our results suggest that there is an association with high,
but not intermediate, baseline concentrations of IL-6 and an
increased likelihood of global cognitive decline upon follow-up.
Interestingly, three of the included studies (Schram et al., 2007;
Singh-Manoux et al., 2014) defined cognitive decline as a change
of ≥3 points in MMSE scores between baseline and follow-
up. The MMSE is a popular cognitive assessment frequently
utilized in large, population based cohorts. It has previously been
suggested that a change in MMSE scores of between 2 and 4
points indicated a reliable change at the 90% confidence level in
non-demented older adults (Stein et al., 2012). Based on this and
to reduce heterogeneity between studies, it may be useful if future
studies adopt this definition when the MMSE is applied to define
cognitive decline.
Mechanisms underlying bidirectional neuro-immune
interactions are becoming increasingly understood (Engelhardt
et al., 2017; Pavlov and Tracey, 2017) with numerous routes into
the CNS being documented. For example, IL-6 has been shown
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FIGURE 2 | Forest plot for the association between high (A) and intermediate (B) peripheral levels of interleukin-6 and future global cognitive decline analysis.
TABLE 4 | Subgroup analyses for the association between high peripheral IL-6 and global cognitive decline analysis.
Main effect Heterogeneity
Studies, n Odds ratio 95% CI Z p χ2 df p I2
DURATION OF FOLLOW-UP
<4 years 4 1.33 1.03 1.73 2.15 0.03 4.05 3 0.26 26%
≥4 years 4 1.59 1.22 2.08 3.44 <0.01 2.60 3 0.46 0%
SAMPLE SIZE AT BASELINE
<1,000 3 1.61 1.12 2.33 2.54 0.01 1.85 2 0.40 0%
≥1,000 5 1.37 1.10 1.72 2.79 <0.01 5.56 4 0.23 28%
METHOD USED TO ASSESS COGNITION
MMSE 4 1.41 1.09 1.82 2.62 <0.01 3.43 3 0.33 13%
Others 4 1.51 1.07 2.13 2.37 0.02 4.67 3 0.20 36%
QUALITY SCORE
<8 3 1.61 0.97 2.67 1.85 0.06 4.34 2 0.11 54%
≥8 5 1.34 1.11 1.61 3.10 <0.01 2.99 4 0.56 0%
CI, Confidence interval; MMSE, Mini Mental State Examination.
to directly cross the BBB in a murine model, albeit at a low level,
via a saturable transport system (Banks et al., 1994). It is also
proposed that peripheral cytokines may have greater access to
the CNS through the circumventricular organs (CVOs), brain
regions which have a high permeability to the circulating milieu.
For example, in rats peripheral injections of IL-6 resulted in the
activation of cells within the CVOs (Harré et al., 2003), suggesting
a potential pathway from periphery to CNS. Other routes into the
CNS include indirect signal propagation at the BBB (Eskilsson
et al., 2014). There is also a significant relationship between IL-6
concentrations in the plasma and cerebrospinal fluid (CSF) in
those with AD (Sun et al., 2003) and a lagged correlation has
been observed in healthy subjects (Agorastos et al., 2014). It is
also possible that the aged CNS is more susceptible to peripheral
inflammatory cytokines. For example, Montagne and colleagues
have shown that the BBB in humans becomes damaged and
permeability is increased within regions responsible for learning
and memory, such as the hippocampus, during aging (Montagne
et al., 2015). Additionally, recurrent insults toward the BBB, due
to recurrent infections or even increased exposure to exogenous
IL-6 (de Vries et al., 1996), have also been shown to increase
BBB permeability (Varatharaj and Galea, 2017). Therefore, it
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FIGURE 3 | Begg’s funnel plots for the association between high (A) and
intermediate (B) peripheral levels of interleukin-6 and future global cognitive
decline analysis. Funnel plot displays the log(odds ratio) against the standard
error, with the pooled effect (solid line) and pseudo 95% confidence limits
(dashed lines).
is possible that BBB dysfunctions, both age-associated and the
presence of underlying infections, may be present within these
populations. Taken together, there is potential for peripheral
IL-6 to gain access into the CNS and this is further exacerbated
during aging.
The periphery to CNS routes raises the possibility
of peripheral IL-6 as a contributing factor toward
neuroinflammation. Conversely, raised IL-6 levels in the
circulation may merely be a reflection of the neuroinflammatory
processes occurring during neurodegeneration and cognitive
decline. For example, in rats it has been shown that IL-6
is secreted from the brain following intracerebroventricular
injections of labeled IL-6 (Chen et al., 1997) and following a
cerebroventricular inflammatory insult (Romero et al., 1996).
Further, in humans, the brain has been shown to secrete IL-6
into the circulation following prolonged exercise (Nybo et al.,
2002). Considering the plethora of sources of IL-6 production
within the CNS, including astrocytes, microglia and neurones
and that IL-6 is upregulated during neurodegeneration (Erta
et al., 2012), it could be possible that some CNS-derived IL-6 may
spill over into the periphery. To elaborate on the cause or effect
conundrum, future studies should explore the effect of chronic
low-grade increases in peripheral IL-6 levels and the effect this
has on the CNS in vivo.
Physiologically, IL-6 is essential for developmental functions
within the CNS including promoting neural differentiation,
modulating adult neurogenesis and controlling neurotrophic
expression (Erta et al., 2012). However, prolonged and
exacerbated IL-6 exposure to the brain has been associated with
numerous neuropathological outcomes. For example, incubating
rat hippocampal precursor cells in vitro with recombinant IL-6
reduced neurogenesis by approximately 50% and increased the
number of apoptotic cells (Monje et al., 2003). Furthermore, the
overproduction of IL-6 by astroglia in transgenic mice decreased
neurogenesis rates within the dentate gyrus by 63% as well
as reducing the proliferation, survival and differentiation of
neural progenitor cells (Vallières et al., 2002). Corroborating this,
and complementing our findings, research utilizing magnetic
resonance imaging has found strong associations between
high blood IL-6 concentrations with hippocampal gray matter
volumes (Marsland et al., 2008; Satizabal et al., 2012), total brain
volumes (Jefferson et al., 2007; Satizabal et al., 2012) and an
increased rate of cortical thinning over time (McCarrey et al.,
2014). These results suggest that long-term exposure of the brain
to increased IL-6 can directly impede neurogenesis and neuronal
health, which may manifest into cognitive decline.
The current findings that non-demented older adults with
high baseline IL-6 are at an increased risk of future cognitive
decline could make it possible of identifying at risk individuals.
To bring this into a clinical setting, a considerable amount
of methodological standardization is required. Firstly, IL-6
peripheral measures are heavily influenced by a circadian rhythm
resulting in considerable inter- and intra-subject variability
(Agorastos et al., 2014). Further, as noted in our literature
analysis, other parameters such as, the type of commercially
available ELISA used, the type of collection tubes used for
blood collection, and the fasted state of participants, all varied
between studies. These methodological issues have been shown
to influence cytokine measurements in clinical research (Zhou
et al., 2010) and is the reasonwhywe chose to look at categorically
defined IL-6 levels as opposed to continuous measures. Exactly
what the specific concentrations of IL-6 classed as “high”
and “low” will become clearer once these methodological
discrepancies have been addressed.
LIMITATIONS
Despite high quality of the studies used in these analyses,
we do accept that there are a few limitations. Firstly, the
methodological designs varied considerably between the studies
included. We anticipated such discrepancies by applying
random-effects analysis throughout. Secondly, we cannot rule
out publication bias since the power of statistical tests used
here to assess publication bias are significantly reduced when
there are fewer than 10 studies in the analysis. Also, we cannot
rule out confounding effects by underlying factors that are
linked to both elevated peripheral IL-6 levels and cognitive
decline, such as cardiovascular disease (CVD) (Compté et al.,
2013). We did, however, extract the most adjusted models,
many included some adjustments for CVD risk (Table 3),
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which would have minimized such an effect. Additionally,
none of the included studies accounted for dietary factors
which are known to influence cognition and IL-6 regulation.
Recent insights utilizing the Whitehall II cohort indicate an
association between dietary patterns, IL-6 concentrations and
cognition in older adults (Ozawa et al., 2017). Also measures
of obesity, such as BMI, are also known to correlate with
peripheral IL-6 concentrations (Charles et al., 2011). Therefore,
it would be interesting if future studies expand on this
dietary and obesity association. Finally, almost all included
studies reported a collated analysis involving a mix of males
and females, therefore potential gender effects could not be
explored.
CONCLUSION
In conclusion, these results add further evidence for the
association between high peripheral inflammation, as measured
by blood IL-6, with future cognitive decline. Specifically, those
with high IL-6 were 1.42 times more likely to experience global
cognitive decline, compared to those with low IL-6. Future
studies should focus on exploring the use of circulating IL-6 as
a biomarker for future cognitive health and standardizing the
processing and measuring of this analyte.
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